Boncresa 60 mg/mL
denosumab-mobz · INJECTION, SOLUTION · Amneal Pharmaceuticals LLC
No Recall History
Plain English
Boncresa is a injection, solution containing denosumab-mobz at 60 mg/mL, taken subcutaneous. Manufactured by Amneal Pharmaceuticals LLC.
Key Facts
- Brand Name
- Boncresa
- Generic Name
- denosumab-mobz
- NDC Code (Product)
70121-2702- Manufacturer
- Amneal Pharmaceuticals LLC
- Strength
- 60 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761456
- Drug Class
- RANK Ligand Inhibitor [EPC]
- Marketing Start
- 12/23/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is Boncresa used for?
Boncresa contains denosumab-mobz. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Boncresa a controlled substance?
Boncresa is not classified as a controlled substance by the DEA.
What is the generic name for Boncresa?
The generic name for Boncresa is denosumab-mobz. There are 1 other brand versions of denosumab-mobz.
What is the NDC code for Boncresa 60 mg/mL?
The NDC (National Drug Code) for Boncresa 60 mg/mL is 70121-2702, listed by Amneal Pharmaceuticals LLC.